Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1007/s10930-020-09942-9

http://scihub22266oqcxt.onion/10.1007/s10930-020-09942-9
suck pdf from google scholar
33185784!7662030!33185784
unlimited free pdf from europmc33185784    free
PDF from PMC    free
html from PMC    free
PDF vom PMID33185784  :  Publisher

suck abstract from ncbi

pmid33185784
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment #MMPMID33185784
  • Jung LS; Gund TM; Narayan M
  • Protein J 2020[Dec]; 39 (6): 619-630 PMID33185784show ga
  • Remdesivir was approved by the U.S.A. Food and Drug administration for emergency use to interfere with the replication of SARS CoV-2 virus (the agent that causes COVID-19) in adults and children hospitalized with severe disease. The crystal structure of the metabolite of remdesivir (Monophosphate of GS-441524) and NSP12-NSP8-NSP7 of SARS CoV-2 virus was recently reported. The crystal structures of ADP-Ribose or AMP and NSP3 of SARS CoV-2 virus were also released, recently. This study compared their binding sites and suggests the crystal structure of NSP3 of SARS CoV-2 virus as an alternative binding site of AMP or ADP-ribose to treat COVID-19. We virtually screened 682 FDA-approved compounds, and the top 10 compounds were selected by analysis of docking scores, (G-score, D-score, and Chemscore) and visual analysis using a structure-based docking approach of NSP3 of SARS CoV-2 virus. All immunization approaches are based on the SARS-CoV-2 virus spike protein. A recent study reported that the D614G mutation in the SARS-CoV-2 virus spike protein reduces S1 shedding and increases infectivity of SARS COV-2 virus. Therefore, if there is a severe change in the spike protein of a modified Coronavirus, all developed vaccines can lose their efficacy, necessitating the need for an alternative treatment method. The top 10 compounds (FDA-approved) in this study are selected based on NSP 3 binding site, and therefore are a potential viable treatment because they will show potential activity for all mutations in the SARS-CoV-2 virus spike protein.
  • |Adenosine Monophosphate/*analogs & derivatives/chemistry/metabolism/pharmacology[MESH]
  • |Alanine/*analogs & derivatives/chemistry/metabolism/pharmacology[MESH]
  • |Antiviral Agents/chemistry/metabolism/*pharmacology[MESH]
  • |Binding Sites[MESH]
  • |COVID-19/*drug therapy/metabolism/virology[MESH]
  • |Coronavirus Papain-Like Proteases/chemistry/metabolism[MESH]
  • |Coronavirus RNA-Dependent RNA Polymerase/chemistry/metabolism[MESH]
  • |Humans[MESH]
  • |Molecular Docking Simulation[MESH]
  • |Protein Conformation/drug effects[MESH]
  • |SARS-CoV-2/chemistry/*drug effects/metabolism[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    619 6.39 2020